An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 29 Oct 2019 Planned End Date changed from 28 Feb 2020 to 16 Jan 2020.
- 29 Oct 2019 Planned primary completion date changed from 28 Feb 2020 to 16 Jan 2020.
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.